Trial Profile

A single-dose study of TMS-007 in patients with ischemic stroke (phase IIa study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JX 10 (Primary)
Indications Cerebral infarction; Stroke
Focus Adverse reactions
Sponsors TMS

Most Recent Events

11 Feb 2022 Results presented at the International Stroke Conference 2022
12 May 2021 According to a Biogen media release, the company exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS, based on positive results from this study.
12 May 2021 Results presented in a Biogen media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com